Who We Are
The Beat Childhood Cancer Research Consortium is a group of 50+ hospitals that offer a worldwide network of childhood cancer clinical trials and collaboration.
Beat Childhood Cancer Research Consortium has a proven track record of managing multi-site clinical trials from start to finish. We have successfully opened 24+ Phase I and II trials for pediatric cancer patients including four Feasibility trials using Molecular Guided Therapy in children with relapsed/refractory solid tumors. This gives children access to the most innovative therapies.
Beat Childhood Cancer Research Consortium has successfully managed four FDA approved IND applications, two FDA approved IDE applications, as well as multiple FDA approved EIND applications. We have obtained Orphan Disease Designation as well as Breakthrough Therapy Designation for diuoromethylornithine (DFMO), a drug designed to prevent relapse in high-risk neuroblastoma. We are continuing to work diligently to move this drug to approval with our pharmaceutical partners with the submission of New Drug Application in 2022 to the FDA for approval.
Beat Childhood Cancer Research Consortium researchers take both a coordinated, multidisciplinary approach AND an individualized approach to childhood cancer care. (1) Our BCC physicians, research coordinators, pharmacists, and nursing teammates take a collaborative approach to care, ensuring we understand each patient’s medical history and unique needs. This makes treatment as safe and effective as possible. (2) Our research consortium is at the forefront of precision medicine, developing treatments based on our patients’ specific genetic or molecular profiles, including a personalized immunotherapy approach.
We have many exciting new trials and collaborations in 2023-2024 that will continue to move us closer to our goal of beating childhood cancer.